Literature DB >> 15315845

Aluminium adjuvants--in retrospect and prospect.

Erik B Lindblad1.   

Abstract

Aluminium compounds have been used as adjuvants in practical vaccination for more than 60 years to induce an early, an efficient and a long lasting protective immunity and are at present the most widely used adjuvants in both veterinary and human vaccines. Although the last two decades of systematic research into the nature of these adjuvants has contributed significantly to understanding their nature and their limitations as Th2 stimulators the more detailed mode of action of these adjuvants is still not completely understood. We have a comprehensive record of their behaviour and performance in practical vaccination, but an empirical approach to optimising their use in new vaccine formulations is still to some extent a necessity. The aim of the present review is to put the recent findings into a broader perspective to facilitate the application of these adjuvants in general and experimental vaccinology.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15315845     DOI: 10.1016/j.vaccine.2004.03.032

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  70 in total

Review 1.  Inactivated influenza vaccines: recent progress and implications for the elderly.

Authors:  Valentina Parodi; Daniela de Florentiis; Mariano Martini; Filippo Ansaldi
Journal:  Drugs Aging       Date:  2011-02-01       Impact factor: 3.923

Review 2.  Vaccines targeting drugs of abuse: is the glass half-empty or half-full?

Authors:  Kim D Janda; Jennifer B Treweek
Journal:  Nat Rev Immunol       Date:  2011-12-16       Impact factor: 53.106

3.  Proposed HPV vaccination syndrome is unsubstantiated.

Authors:  Helen Petousis-Harris
Journal:  Clin Rheumatol       Date:  2015-10-21       Impact factor: 2.980

4.  Proteasome-independent major histocompatibility complex class I cross-presentation mediated by papaya mosaic virus-like particles leads to expansion of specific human T cells.

Authors:  Denis Leclerc; Diane Beauseigle; Jérome Denis; Hélène Morin; Christine Paré; Alain Lamarre; Réjean Lapointe
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

5.  Transcutaneous immunization with cross-reacting material CRM(197) of diphtheria toxin boosts functional antibody levels in mice primed parenterally with adsorbed diphtheria toxoid vaccine.

Authors:  Paul Stickings; Marisa Peyre; Laura Coombes; Sylviane Muller; Rino Rappuoli; Giuseppe Del Giudice; Charalambos D Partidos; Dorothea Sesardic
Journal:  Infect Immun       Date:  2008-01-28       Impact factor: 3.441

Review 6.  Recent progress in adjuvant discovery for peptide-based subunit vaccines.

Authors:  Fazren Azmi; Abdullah Al Hadi Ahmad Fuaad; Mariusz Skwarczynski; Istvan Toth
Journal:  Hum Vaccin Immunother       Date:  2013-12-03       Impact factor: 3.452

7.  IL-4 promotes stromal cell expansion and is critical for development of a type-2, but not a type 1 immune response.

Authors:  Diana Cortes-Selva; Andrew Ready; Lisa Gibbs; Bartek Rajwa; Keke C Fairfax
Journal:  Eur J Immunol       Date:  2019-01-03       Impact factor: 5.532

8.  Primary CD8+ T-cell response to soluble ovalbumin is improved by chloroquine treatment in vivo.

Authors:  Bruno Garulli; Maria G Stillitano; Vincenzo Barnaba; Maria R Castrucci
Journal:  Clin Vaccine Immunol       Date:  2008-08-27

Review 9.  Design opportunities for actively targeted nanoparticle vaccines.

Authors:  Tarek M Fahmy; Stacey L Demento; Michael J Caplan; Ira Mellman; W Mark Saltzman
Journal:  Nanomedicine (Lond)       Date:  2008-06       Impact factor: 5.307

10.  Vaccine adjuvants alter TCR-based selection thresholds.

Authors:  Laurent Malherbe; Linda Mark; Nicolas Fazilleau; Louise J McHeyzer-Williams; Michael G McHeyzer-Williams
Journal:  Immunity       Date:  2008-05-01       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.